Patents
Literature
10 results about "Immunodeficiency" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunodeficiency is a state in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. Most cases of immunodeficiency are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection, extremes of age, and environmental factors, such as nutrition. In the clinical setting, the immunosuppression by some drugs, such as steroids, can be either an adverse effect or the intended purpose of the treatment. Examples of such use is in organ transplant surgery as an anti-rejection measure and in patients suffering from an overactive immune system, as in autoimmune diseases. Some people are born with intrinsic defects in their immune system, or primary immunodeficiency. A person who has an immunodeficiency of any kind is said to be immunocompromised. An immunocompromised person may be particularly vulnerable to opportunistic infections, in addition to normal infections that could affect everyone. Immunodeficiency also decreases cancer immunosurveillance, in which the immune system scans the body's cells and kills neoplastic ones.
Application of Lactobacillus rhamnosus fermented ginseng freeze-dried powder in the preparation of immunomodulatory drugs
This invention discloses the application of *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder in the preparation of immunomodulatory drugs, belonging to the field of bio-fermentation and immunomodulation technology. The *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder is prepared by fermenting ginseng with *Lactobacillus rhamnosus*. The rare ginsenosides include at least one of Ck, Rk1, Rh4, and Rg5. The immunomodulatory drug is used to improve cyclophosphamide-induced immunodeficiency. The amount of *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder added to the immunomodulatory drug is 10%-50% (mass fraction). The preparation method of the *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder is as follows: S1, ginseng pretreatment; S2, strain activation; S3, fermentation culture; S4, freeze-dried powder preparation. This invention has the technical effects of high bioavailability of ginseng active ingredients, significant immunomodulatory effect, good safety, and effective improvement of cyclophosphamide-induced immunodeficiency.
Owner:JILIN AGRI SCI & TECH COLLEGE
2-amino-4-methylquinazoline compounds, processes for their preparation, uses and pharmaceutical compositions
This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Irak4 degrader and uses thereof
This invention relates to an IRAK4 degrading agent and its uses. This degrading agent can be used to treat or prevent diseases such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, cell death-related conditions, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.
Owner:BEIJING SHUANGHE RUNCHUANG TECH CO LTD
A composition for preventing and improving sarcopenia, immunodeficiency caused by cancer and related treatments, and a preparation method and application thereof
The application belongs to the technical field of biological medicine, and provides a composition for preventing and improving cancer and sarcopenia caused by related treatment and immunodeficiency, a preparation method and application thereof.The composition comprises the following components: nucleotides, beta-hydroxy beta-methyl butyrate, arginine, histidine, glutathione, fish oil, seaweed oil and vitamin E.The composition has remarkable effects on improving cancer and sarcopenia caused by related treatment and immunodeficiency in the compounding of the components.
Owner:THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Thienopyrimidine derivatives, processes for their preparation, uses and pharmaceutical compositions
PendingCN122080012Ahigh selectivityStrong kinase inhibitory activityOrganic active ingredientsNervous disorderImmunologic disordersAutoimmune condition
This invention belongs to the field of pharmaceutical technology and relates to thienopyrimidine derivatives, their preparation methods, uses, and pharmaceutical compositions. The thienopyrimidine derivatives, as shown in formula (I), are phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors and can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, kidney diseases, cardiovascular diseases, inflammation, metabolic / endocrine dysfunction, or neurological diseases.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
TGFBeta signal convertor
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. 20 24 20 36 04 29 M ay 2 02 4 A B S T R A C T 2 0 2 4 2 0 3 6 0 4 2 9 M a y 2 0 2 4
Owner:REGENERON PHARMACEUTICALS INC
Anti-PVRIG antibody and its use
This disclosure provides an anti-PVRIG antibody, a nucleic acid molecule encoding the anti-PVRIG antibody, and an expression vector and host cells used for the expression of the anti-PVRIG antibody. This disclosure further provides a method for preventing and treating cancer and immunodeficiency by administering the anti-PVRIG antibody.
Owner:WUXI BIOLOGICS IRELAND LIMITED
Method for establishing a naked mole rat immunodeficient animal model
ActiveCN119949273BImmune intervention has significant effectsShort cycleOrganic active ingredientsAnimal husbandryPhysiologyImmunodeficiency
The application relates to the field of animal model construction, in particular to a naked mole rat immunodeficiency animal model establishment method, which is established by regularly injecting a naked mole rat with a chloromethylene bisphosphonate-liposome, and the naked mole rat immunodeficiency animal model is established. The naked mole rat immunodeficiency animal model establishment method has the advantages of short cycle, simple operation, good reproducibility, remarkable immune intervention effect, and can be used for the research on the related functions of the naked mole rat macrophage action mechanism.
Owner:THE NAVAL MEDICAL UNIV OF PLA
Construction method of humanized sirpalpha immunodeficient mouse and application thereof in human immune reconstruction
PendingCN122235233AImprove target specificityReduce off-target riskMicroinjection basedStable introduction of DNAPeripheral blood mononuclear cellRAG2
This invention discloses a humanized Sirpα The construction methods of immunodeficient mice and their application in human immune reconstitution belong to the field of medical experimental model construction technology. Rag2 ‑ / ‑ IL2rg ‑ / ‑ Using animals with T, B, and NK cell immune dysfunction caused by mutations as the background strain, sgRNA and dsDNA were specifically designed, and their endogenous components were processed using CRISPR / Cas9 gene editing technology. Sirpα The entire genome was modified to be humanized, thus creating a humanized genome. Sirpα Immunodeficient mice. This method is simple to operate, highly reproducible, and constructs a fully humanized mouse. Sirpα Immunodeficient mice exhibit a higher immunodeficient phenotype and can achieve a higher rate of human T cell chimerism after transplantation with human peripheral blood mononuclear cells, while effectively reducing the risk of graft-host disease.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Use of asparagine for the preparation of a medicament for the treatment of an immunodeficiency disease and / or for the treatment of a viral infection
This invention relates to the application of asparagine in the preparation of antiviral drugs and / or drugs for treating immunodeficiency diseases, belonging to the field of biomedical technology. This invention is the first to discover that asparagine can induce TBK1 activation, increasing the expression of type I interferon in the body under viral infection conditions, enabling the body to rapidly respond to host defense mechanisms and enhance immunity when subjected to viral infection, thereby achieving a broad-spectrum antiviral effect. It also discloses a new use of asparagine as a TBK1 agonist, which can be used in the preparation of antiviral drugs, drugs for treating immunodeficiency diseases, and products for enhancing immunity. Furthermore, asparagine is a non-essential amino acid for the human body, possessing characteristics such as being green, safe, and environmentally friendly; it can be used as a functional additive in pharmaceuticals, health products, or food products.
Owner:SHANDONG UNIV